For solid tumors, the role of JAK inhibition was examined in models of IL-6-driven breast, ovarian, and prostate cancers using the JAK1/2 inhibitor AZD1480, which led to the suppression of tumor growth [91]. This evidence concerns the gene IL6 and neoplasm.